PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 14, 2026Stem Cell Research0 citationsOpen Access

Generation of four induced pluripotent stem cell lines from Korean patients with Huntington’s disease (IPBi001-A, IPBi002-A, IPBi003-A, IPBi004-A)

View Full Paper
MLMiju LeeMLMiju LeeYKYoon-Eun Kim

Key Points

  • The aim was to generate induced pluripotent stem cell lines from patients with Huntington’s disease.
  • Established iPSC lines from peripheral blood mononuclear cells using Sendai virus-based reprogramming.
  • Characterized iPSCs using immunocytochemistry for pluripotency markers.
  • Assessed trilineage differentiation potential in vitro.
  • Verified normal karyotypes and STR profiles matching parental PBMCs.
  • Generated four patient-specific iPSC lines demonstrating pluripotency.
  • All iPSC lines showed successful differentiation into three germ layers.
  • iPSCs maintained normal genetic profiles with no remnants of the Sendai virus.

Abstract

Human induced pluripotent stem cell (iPSC) lines were generated from peripheral blood mononuclear cells (PBMCs) of four Korean patients with Huntington’s disease using a non-integrating Sendai virus-based reprogramming method. The iPSC lines expressed pluripotency markers, as confirmed by immunocytochemistry (OCT4, NANOG, SSEA-4) and flow cytometry (TRA-1-60, TRA-1-81, SSEA-4), and showed trilineage differentiation potential in vitro . All lines retained normal karyotypes and short tandem repeat (STR) profiles identical to parental PBMCs, with complete clearance of Sendai virus. These patient-derived iPSCs provide a valuable resource for Huntington’s disease modeling, drug discovery, and efficacy evaluation

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lee et al. (2026) studied this question.

synapsesocial.com/papers/69b4fc7fb39f7826a300d57dhttps://doi.org/10.1016/j.scr.2026.103963
Ask AI
Helpful
Bookmark
Share
View Full Paper